Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
5Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Inhibitor Therapeutics, Inc. (INTI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
4Distinct source URLs
7High confidence
0.832Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Inhibitor Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
FRAMESHIFT-MANAGEMENT-INC
FRAMESHIFT-MANAGEMENT-INC
92%
Frameshift shall provide the Company with consulting services for biostatistics, regulatory, business development and strategic consulting in support of Company’s programs
JOHNS-HOPKINS-UNIVERSITY
JOHNS-HOPKINS-UNIVERSITY
90%
On December 12, 2023, the Company entered into an Exclusive License Agreement (the “Agreement”) with Johns Hopkins University ("JHU").
MAYNE-PHARMA
MAYNE-PHARMA
85%
License Agreement by and between the Company and Mayne Pharma, dated December 13, 2022
SCIQUUS-INC
SCIQUUS-INC
85%
Master Clinical Services Agreement, dated June 15, 2015, by and between the Company and SciQuus, Inc.
Inhibitor Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
INSTITUTIONAL-INVESTOR
INSTITUTIONAL-INVESTOR
92%
On February 24, 2026, Inhibitor Therapeutics, Inc. (the “ Company ”) filed a Current Report on Form 8-K (the “February 24 th Form 8-K”) with the Securities and Exchange Commission (the “Commission”) …
MAYNE-PHARMA-VENTURES-PTY-LTD
MAYNE-PHARMA-VENTURES-PTY-LTD
92%
As of March 31, 2026 and December 31, 2025, deferred revenue consisted of $ 3 million of royalties advanced by Mayne Pharma under the Third Amended Supply and License Agreement.
ses of the civil False Claims Act or the civil monetary penalties statute, which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federa…
Reciprocal relationship from ORANY graph: Reciprocal relationship from INTI graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from INTI graph: Reciprocal relationship from ORAN…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
increase in the future, depending on the results from our upcoming FDA meetings. General and Administrative Expenses . We incurred approximately $0.4 million in general and administrative expenses du…
Inhibitor Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INTI-DEBT-10306
Warrants outstanding: 53093902
90%
xbrl warrant detail from xbrl 2018-12-31.
Inhibitor Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Inhibitor Therapeutics, Inc..
Inhibitor Therapeutics, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Inhibitor Therapeutics, Inc..
Inhibitor Therapeutics, Inc. Extended Supply Chain Network
